Histopathologic Features of Kidney Tumors and Comparison of Patients Treated with Radical and Partial Nephrectomy at Osijek University Hospital Center from 2017 until the end of 2021
The objective of this study was to present results of kidney tumor treatment at Osijek University Hospital Center over a 5-year period and to compare the outcomes between patients treated with radical nephrectomy (RN) and partial nephrectomy (PN). From November 2016 until the end of 2021, there w...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2023-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/447451 |
| Summary: | The objective of this study was to present results of kidney tumor treatment at Osijek
University Hospital Center over a 5-year period and to compare the outcomes between patients treated
with radical nephrectomy (RN) and partial nephrectomy (PN). From November 2016 until the end of
2021, there were 280 consecutive PNs and RNs included in this cross-sectional study. Exclusion criteria
were nephrectomies due to non-oncologic reasons and transitional cell carcinoma. There were 229
RNs and 51 PNs, median age of all patients was 62.5 (range 34-84) years. In the RN group, there were
197 renal cell carcinomas (RCC), predominantly clear-cell subtype, while among others there were 8
multilocular cystic renal neoplasms of low malignant potential (MCRNLMP) and 6 oncocytomas and
angiomyolipomas each. There were 44 RCCs, 4 oncocytomas, 1 MCRNLMP and 2 cysts removed with
PN; median R.E.N.A.L. score was 5. RN group had greater tumor diameters and higher tumor grade,
higher postoperative creatinine levels and complications of higher grade. There was no difference in
median hospital stay (6 days) and follow-up (20 months). With regard to oncologic safety, preservation
of kidney function and lower overall morbidity, PN should be preferred to RN whenever oncologically
safe and technically feasible. |
|---|---|
| ISSN: | 0353-9466 1333-9451 |